Apr 27 2023: This sample was originally reported as containing Fluorexetamine (3-Fluoro-2-oxo PCE). A certified reference standard became available for 2-Fluoro-2-oxo PCE in early 2023.
All samples analyzed by the DrugsData lab prior to early 2023 that were reported as containing Fluorexetamine have been reexamined in comparison to this new standard. They have all been retroactively revised; they all contain 2-Fluoro-2-oxo PCE, including this sample. To date, no samples tested by DrugsData have contained 3-Fluoro-2-oxo PCE.
Dec 20 2022: The secondary unidentified may be a positional isomer of the more abundant one. (thank you, Y.)
May 5 2022: Fluorexetamine has been confirmed by comparison to certified reference standard.
Apr 22 2022: Unidentified substance has been tentatively identified as Fluorextamine with the second chemical likely the hydroxylimine variant of the parent compound (thank you, K.). We are working to finalize this identification.
Send in a sample for testing
DrugsData tests all psychoactive drugs including ecstasy tablets, powders, research chemicals, novel pschoactive substances, and other drugs through our licensed laboratory. Ecstasy/Molly tablets cost $100. Recreational drug powder/crystal/blotter costs $100. Pharmaceuticals, supplements and all others cost $150 per analysis.
Should the public have access to independent analysis of the products they consume?
The vast majority of analyses of over-the-counter, prescription, and recreational drugs are performed in secret with no independent oversite or review. No other historical record, free from politically-controlled agencies, is currently available in North America nor most other parts of the world.
DrugsData, a project of Erowid Center, needs the support of professionals, students, parents, individuals with means, and small foundations for a total yearly budget of around $120,000 USD. Erowid Center's general budget and the co-pays we require fund most of this cost.
Unidentified Substance #2: 20 parts (since identified as 2'-Fluoro-2-oxo-PCE after first being misidentified as 3'-Fluoro-2-oxo-PCE)
All samples analyzed by the DrugsData lab prior to early 2023 that were reported as containing Fluorexetamine have been reexamined in comparison to this new standard. They have all been retroactively revised; they all contain 2-Fluoro-2-oxo PCE, including this sample. To date, no samples tested by DrugsData have contained 3-Fluoro-2-oxo PCE.
Dec 20 2022: The secondary unidentified may be a positional isomer of the more abundant one. (thank you, Y.)
May 5 2022: Fluorexetamine has been confirmed by comparison to certified reference standard.
Apr 22 2022: Unidentified substance has been tentatively identified as Fluorextamine with the second chemical likely the hydroxylimine variant of the parent compound (thank you, K.). We are working to finalize this identification.